Evidence map›Paper›PMID 36801633›Full record

ReviewJournal of infection and public health2023

Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis.

Aysel Karagoz, Huseyin Tombuloglu, Moneerah Alsaeed, Guzin Tombuloglu, Abdullah A AlRubaish, Amal Mahmoud, Samira Smajlović, Sabahudin Ćordić, Ali A Rabaan, Ebtesam Alsuhaimi

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of infection and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06223919 (Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia), which is not on this map. Cited by 154 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 8 pooled it
37.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06223919 phase3active not recruitingnot on this map

Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia

TypeinterventionalSponsorUniversidad Nacional de ColombiaRan2023 to 2025Enrolled8,686ConditionsMonkeypoxArmsLC16m8
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 8 syntheses or guidelines pooled it, 267 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Treatment of mpox with tecovirimat under expanded access use in the Central African Republic.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Article
  10. Article
  11. A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Aysel KaragozQuality Assurance Department, Turk Pharmaceutical and Serum Ind. Inc., Ankara, Turkey.
Huseyin TombulogluDepartment of Genetics Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 34221, Saudi Arabia. Electronic address: htoglu@iau.edu.sa.
Moneerah AlsaeedDepartment of Genetics Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 34221, Saudi Arabia.
Guzin TombulogluDepartment of Biophysics, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 34221, Saudi Arabia.
Abdullah A AlRubaishCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Amal MahmoudDepartment of Bioinformatics, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt.
Samira SmajlovićLaboratory Diagnostics Institute Dr. Dedić, Bihać 77000, Bosnia and Herzegovina.
Sabahudin ĆordićCantonal hospital "Dr. Irfan Ljubijankić", Microbiological laboratory, Bihać 77000, Bosnia and Herzegovina.
Ali A RabaanMolecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; Department of Public Health and Nutrition. The University of Haripur, Haripur 22610, Pakistan.
Ebtesam AlsuhaimiBiology Department, College of Science and Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Imam Abdulrahman Bin Faisal University · SAAlfaisal University · SAUniversity of Bihać · BAUniversity of Sadat City · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monkeypox virus (MPXV) is a double-stranded DNA virus belonging to the Poxviridae family of the genus Orthopoxvirus with two different clades known as West African and Congo Basin. Monkeypox (MPX) is a zoonosis that arises from the MPXV and causes a smallpox-like disease. The endemic disease status of MPX was updated to an outbreak worldwide in 2022. Thus, the condition was declared a global health emergency independent of travel issues, accounting for the primary reason for its prevalence outside Africa. In addition to identified transmission mediators through animal-to-human and human-to-human, especially sexual transmission among men who have sex with men came to prominence in the 2022 global outbreak. Although the severity and prevalence of the disease differ depending on age and gender, some symptoms are commonly observed. Clinical signs such as fever, muscle and headache pain, swollen lymph nodes, and skin rashes in defined body regions are standard and an indicator for the first step of diagnosis. By following the clinical signs, laboratory diagnostic tests like conventional polymerase chain reaction (PCR) or real-time PCR (RT-PCR) are the most common and accurate diagnostic methods. Antiviral drugs such as tecovirimat, cidofovir, and brincidofovir are used for symptomatic treatment. There is no MPXV-specific vaccine; however, currently available vaccines against smallpox enhance the immunization rate. This comprehensive review covers the MPX disease history and the current state of knowledge by assessing broad topics and views related to disease origin, transmission, epidemiology, severity, genome organization and evolution, diagnosis, treatment, and prevention.

Indexed as

Mpox, MonkeypoxSexual and Gender MinoritiesSmallpoxAnimalsAntiviral AgentsHomosexuality, MaleHumansMaleMonkeypox virusAntiviral AgentsDiagnosisGenomeMonkeypox virusMpoxSusceptibilityTransmission

Identifiers

PMID36801633
PMCPMC9908738
OpenAlexW4319786369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.